NEW YORK (GenomeWeb) – The Epilepsy Foundation has teamed with Pfizer and Intellimedix to create a drug discovery platform targeted toward patients with genetic forms of epilepsy, the foundation said today.

The partners hope the drug screening platform will be used to create individualized treatments for people with Dravet Syndrome, a severe form of genetic epilepsy, and for other types of this disease for which there are only limited treatment options.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: oral microbiomes of dogs and their owners, Plasmodium vivax population structure, and more.

The American Society of Human Genetics has issued a position statement on genetic testing of children.

The White House seeks to update how biotechnology products are regulated.

Team science leads some researchers to get lost in the shuffle, the Chronicle of Higher Education reports.

Jul
14
Sponsored by
Agilent Technologies

This online seminar will outline a recent example of the use of molecular barcoding in combination with next-generation sequencing to detect somatic mosaicism in cancer patients.